Buy the dip, not the rip.
$ETON Did anyone really think that Biorphen®, Rezipres®, and Cysteine Hydrochloride all of which are for indications that are not for rare diseases were long term holdings for a rare disease company?
Like they said in their CC, they are now focusing all their $$ into researching and developing therapies for RARE diseases with unmet need They have spent the entire 1H of 2022 establishing a relationship specialist in pediatric endocrinology and metabolic genetics.
They are in a good position to use those partnerships to further their presence in those specialties. They already have 2 product candidates that will fill a void in these spaces.
Although it might not seem like an impressive sum, but ETON made $7.9 Mill in Q2 alone and is expected to make $20-25 Mill in revenue. This is all on top of their current cash on hand that is $17Mill. They have no need to do an offering for dilutive funding. They are NOT desperate, moving forward, they are investing in RARE diseases
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
